Study on the Value of Alirocumab Combined with Atorvastatin in the Treatment of Coronary Heart Disease Combined with Hyperlipidemia
Objective To investigate the therapeutic effect of alirocumab combined with atorvastatin in coronary atherosclerotic heart disease(hereinafter referred to as coronary heart disease)complicated with hyperlipidemia.Methods 100 patients with coronary heart disease combined with hyperlipidemia admitted to Gaotang County People's Hospital Affiliated to Jining Medical University from December 2021 to December 2023 were prospective randomly se-lected as the study subjects,and they were divided into two groups of 50 cases each by using the method of random-ized number table.The control group received atorvastatin treatment,and the observation group received atorvastatin+alirocumab treatment.Compare the therapeutic effect,blood lipid index and cardiac function index of the two groups.Results The total treatment efficiency of the observation group was 98.00%,higher than that of the control group(84.00%),the difference was statistically significant(χ2=4.396,P<0.05).Before treatment,the difference be-tween the lipid indexes and cardiac function indexes of the two groups was not statistically significant(both P>0.05);after treatment,total cholesterol,triglyceride,low-density lipoprotein cholesterol,left ventricular end-systolic internal diameter and left ventricular end-diastolic internal diameter of the observation group were lower than those of the con-trol group,and high-density lipoprotein cholesterol and left ventricular ejection fraction were higher than those of the control group,and the differences were statistically significant(all P<0.05).Conclusion The effect of alirocumab com-bined with atorvastatin in the treatment of coronary heart disease combined with hyperlipidemia is more significant,which can improve the patients'hyperlipidemic symptoms and promote the recovery of cardiac function.
万方数据
维普
